99B0 Stock Overview
Engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Quia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0027 |
| 52 Week High | SEK 0.015 |
| 52 Week Low | SEK 0.0001 |
| Beta | 0.44 |
| 11 Month Change | 68.75% |
| 3 Month Change | -22.86% |
| 1 Year Change | -27.03% |
| 33 Year Change | -99.95% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 99B0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 17.4% | 0.8% | -1.3% |
| 1Y | -27.0% | -17.5% | 7.4% |
Return vs Industry: 99B0 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 99B0 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 99B0 volatility | |
|---|---|
| 99B0 Average Weekly Movement | 65.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 99B0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 99B0's weekly volatility has decreased from 1634% to 65% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Marcus Bosson | www.quiapeg.com |
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
Quia Pharma AB (publ) Fundamentals Summary
| 99B0 fundamental statistics | |
|---|---|
| Market cap | €4.23m |
| Earnings (TTM) | -€1.20m |
| Revenue (TTM) | €430.65k |
9.8x
P/S Ratio-3.5x
P/E RatioIs 99B0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 99B0 income statement (TTM) | |
|---|---|
| Revenue | SEK 4.99m |
| Cost of Revenue | SEK 1.30m |
| Gross Profit | SEK 3.69m |
| Other Expenses | SEK 17.55m |
| Earnings | -SEK 13.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0093 |
| Gross Margin | 73.94% |
| Net Profit Margin | -277.59% |
| Debt/Equity Ratio | 9.6% |
How did 99B0 perform over the long term?
See historical performance and comparison